Only about 20% of patients have a long-term survival benefit from this treatment, and some patients experience treatment response and long overall survival (OS) despite a low tissue PD-L1 expression [2, 11, 12] demonstrating the complex interaction between the tumor microenvironment and the host immune system. Here, CD274 is linked to neoplasm.